HALISTER1: OMERS Administration Corporation and Subsidiaries - DBRS Rating Report

OMERS Administration Corporation and Subsidiaries - DBRS Rating Report

Alert: HALISTER1
Source: DBR (Dominion Bond Rating Service)

Tickers
OMERS CN (OMERS Administration Corp)

People
Geetika Gupta (DBRS Ltd)
Jamie Feehely (DBRS Ltd)
Paul Bretzlaff (DBRS Ltd)

Topics
Fixed Income Research
Credit Analysis Research
Credit Research
Investment Research
Issuer Focused Research

To de-activate this alert, click here
To modify this alert, click here

UUID: 7947283

HALISTER: Facebook 2Q Adj. EPS, Revenue Top Highest Estimates

Facebook 2Q Adj. EPS, Revenue Top Highest Estimates

(Bloomberg) -- 2Q adj. EPS 97c, est. 82c (range 76c-90c); rev. $6.44b, est. $6.01b (Range $5.83b-$6.22b).
  • FB jmps 6.7% post-mkt
  • Call 5pm 866.554.3009 pw 41929608
  • NOTE: FB earlier record $123.50 intraday (IPO’d at $38) on >1.7x avg daily volume, extending YTD gain to 17.5%
  • Earlier, Facebook May Be Reaching Plateau in Mobile Time Spent Per User: BI; July 26, PREVIEW FACEBOOK 2Q: Analysts See Strong Quarter on Mobile Ads
Statement
Alert: HALISTER
Source: BFW (Bloomberg First Word)

Tickers
FB US (Facebook Inc)

To de-activate this alert, click here

UUID: 7947283

HALISTER: Amgen Boosts Forecast After 2Q Beats Estimates on Enbrel, Prolia

Amgen Boosts Forecast After 2Q Beats Estimates on Enbrel, Prolia

(Bloomberg) -- Amgen sees 2016 adj EPS $11.10-$11.40, saw $10.85-$11.20 (April 28), est. $11.17 (range $10.71-$12.23)
  • Sees 2016 rev. $22.5b-$22.8b, saw $22.2b-$22.6b, est. $22.57b (range $22.19b-$23.37b)
  • Still sees 2016 capex $700m
  • 2Q adj EPS $2.84, est. $2.74 (range $2.52-$2.94)
  • 2Q rev. $5.69b, est. $5.58b (range $5.34b-$5.75b)
    • Enbrel rev. $1.48b, est. $1.41b
    • Neulasta rev. $1.15b, est. $1.17b
    • Aranesp rev. $504m, est. $518.4m
    • Prolia rev. $441m, est. $389.1m
    • Xgeva rev. $381m, est. $381.0m
    • Sensipar/Mimpara rev. $389m, est. $380.9m
    • Epogen rev. $331m, est. $296.8m
    • Neupogen rev. $196m, est. $214.2m
    • Kyprolis rev. $172m, est. $182.1m
    • Blincyto rev. $30m, est. $28.4m
    • Repatha rev. $27m, est. $24.8m
  • Expects Repatha cardiovascular outcomes data in 1Q17, Kyprolis Phase 3 first-line multiple myeloma data in 2H16, erenumab (AMG 334) Phase 3 data in chronic migraine in 2H
  • Conf. call 5pm, 877-233-5736 pw 43870367; preview
Alert: HALISTER
Source: BFW (Bloomberg First Word)

Tickers
AMGN US (Amgen Inc)
AZN LN (AstraZeneca PLC)
4568 JP (Daiichi Sankyo Co Ltd)
GSK LN (GlaxoSmithKline PLC)
PFE US (Pfizer Inc)

To de-activate this alert, click here

UUID: 7947283